U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q/A

(Amendment No. 1 to Form 10-Q)

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2021.

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 000-51074

image provided by client

BIOFORCE NANOSCIENCES HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Nevada	74-3078125

| (Address of Principal Executive Offices) | (Zip Code) |

| Registrant’s telephone number, including area code: 757-306-6090 | |

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐

| Non-accelerated filer ☒ | Smaller reporting company ☒ |

| Emerging growth company ☐ | |

-1-

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date: At July 29, 2021 the registrant had outstanding 29,271,755 shares of common stock, par value $0.001 per share.

Explanatory Note:

The amendment No. 1 to FORM 10Q filed on July 29, 2021 is being filed to fix a technological error during the original filing of the iXBRL which had a code error whereas the majority of the Management Discussion, other items, and the exhibit sections where omitted during filing. The amendment here forth corrects the code error, accordingly. No other items have been corrected or changed with this amended filing.

	PAGE

| PART I | |

| Item 1.Condensed Consolidated Unaudited Financial Statements | 3 | | Item 2. Management’s Discussion and<br> Analysis of Financial Condition and Results of Operations | 11 | | --- | --- | | Item 3. Quantitative and Qualitative Disclosures<br> About Market Risk | 16 | | Item 4. Controls and Procedures | 16 | | PART II | | | Item 1. Legal Proceedings | 18 | | Item 1A. Risk Factors | 18 | | Item 2. Unregistered Sales of Equity Securities<br> and Use of Proceeds | 18 | | Item 3. Defaults Upon Senior Securities | 18 | | Item 4. Mining Safety Disclosures | 18 | | Item 5. Other Information | 18 | | Item 6. Exhibits | 19 | | Signatures | 19 |

-2-

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

BIOFORCE NANOSCIENCES HOLDINGS, INC.
	FINANCIAL REPORTS

| | AT |

| | JUNE 30, 2021 | | INDEX TO FINANCIAL STATEMENTS | | | --- | --- |

| Condensed Consolidated Balance Sheets at June 30, 2021- Unaudited and December 31, 2020 | 4 |

| Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2021 and 2020 - Unaudited | 5 |

| Condensed Consolidated Statements of Cash Flows for the Three and Six Months Ended June 30, 2021 and 2020 - Unaudited | 6 |

| Condensed Consolidated Statements of Stockholders' Equity for the Three and Six Months Ended June 30, 2021 and 2020– Unaudited | 7 |

| Notes to the Condensed Consolidated Unaudited Financial Statements | 8-10 |

-3-

BioForce Nanosciences Holdings, Inc., and Subsidiary

CONDENSED CONSOLIDATED BALANCE SHEETS - UNAUDITED

| | | 2020 | |

| Cash | 27,305 | $ | 39,865 |

| Prepaid Expenses | 100 | | - | | Total Current Assets | 27,405 | | 39,865 | | Total Assets | 27,405 | $ | 39,865 | | LIABILITIES AND STOCKHOLDERS' DEFICIT | | | | | Current Liabilities | | | |

| Accounts Payable and Accrued Expenses | 1,032 | $ | 5,090 |

| Accrued Board of Directors Compensation | 539,017 | | 327,517 |

| Due to Related Parties | 114,658 | | 67,166 | | Total Current Liabilities | 654,707 | | 399,773 | | Total Liabilities | 654,707 | | 399,773 | | Stockholders' Deficit | | | |

| Common Stock - 0.001 Par; 900,000,000 Shares Authorized, 29,271,755 Issued and Outstanding, Respectively | 29,272 | | 29,272 |

| Additional Paid-In-Capital | 158,781,127 | | 158,781,127 |

| Accumulated Deficit | (159,437,701) | | (159,170,307) | | Total Stockholders' Deficit | (627,302) | | (359,908) | | Total Liabilities and Stockholders' Deficit | 27,405 | $ | 39,865 |

All values are in US Dollars.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

-4-

BioForce Nanosciences Holdings, Inc., and Subsidiary

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - UNAUDITED

| | 2021 | | 2020 | | 2021 | | 2020 | | | Sales | $ | - | $ | - | $ | - | $ | - | | Cost of Sales | | - | | - | | - | | - | | Gross Profit | | - | | - | | - | | - | | Operating Expenses | | | | | | | | |

| Board of Directors Compensation | | 105,750 | | 105,173 | | 211,500 | | 158,114,863 |

| General and Administrative | | 16,565 | | 21,537 | | 55,894 | | 53,205 | | Total Expenses | | 122,315 | | 126,710 | | 267,394 | | 158,168,068 | | Net Loss for the Period | $ | (122,315) | $ | (126,710) | $ | (267,394) | $ | (158,168,068) | | Weighted Average Number of Common Shares - Basic and Diluted | | 29,271,755 | | 15,271,755 | | 29,271,755 | | 15,271,402 | | Net Loss for the Period Per Common Shares - Basic and Diluted | $ | (0.00) | $ | (0.00) | $ | (0.01) | $ | (10.36) |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

-5-

BioForce Nanosciences Holdings, Inc., and Subsidiary

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - UNAUDITED
For the Six Months Ended June 30,	2021		2020

| Cash Flows from Operating Activities | | | | | | Net Loss for the Period | $ | (267,394) | $ | (158,168,068) | | Non-Cash Adjustments: | | | | |

| Common and Preferred Stock Issued for Current Year Board of Directors Compensation | | - | | 158,000,000 | | Changes in Assets and Liabilities: | | | | |

| Prepaid Expenses | | (100) | | 3,047 |

| Accounts Payable and Accrued Expenses | | (4,058) | | (10,248) |

| Accrued Board of Directors Compensation | | 211,500 | | 114,863 | | Net Cash Flows Used In Operating Activities | | (60,052) | | (60,406) | | Cash Flows from Investing Activities | | - | | - | | Cash Flows from Financing Activities | | | | |

| Proceeds from Related Parties | | 47,492 | | 47,376 | | Net Cash Flows Provided by Financing Activities | | 47,492 | | 47,376 | | Net Change in Cash | | (12,560) | | (13,030) | | Cash - Beginning of Period | | 39,865 | | 52,895 | | Cash - End of Period | $ | 27,305 | $ | 39,865 | | Cash Paid During the Period for: | | | | |

| Interest | $ | - | $ | - |

| Income Taxes | $ | - | $ | - | | Supplemental Disclosures of Non Cash Investing and Financing Activities: | | | | |

| Common Stock Issued to Pay Stock Payable | $ | - | $ | 1,339 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

-6-

BioForce Nanosciences Holdings, Inc., and Subsidiary

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2021 AND 2020 - UNAUDITED
	Common Stock		Preferred Stock - A			Additional				Total

| | Shares | Amount | Shares | Amount | | Capital | | Deficit | | Equity | | Balance - April 1, 2020 | 15,271,755 | 15,272 | 2,000,000 | 2,000 | $ | 158,793,127 | $ | (158,803,110) | $ | 7,289 | | Net Loss for the Period | - | - | - | - | | - | | (126,710) | | (126,710) | | Balance - June 30, 2020 | 15,271,755 | 15,272 | 2,000,000 | 2,000 | $ | 158,793,127 | $ | (158,929,820) | $ | (119,421) |

All values are in US Dollars.

	Common Stock		Preferred Stock - A			Additional				Total

| | Shares | Amount | Shares | Amount | | Capital | | Deficit | | Equity | | Balance - April 1, 2021 | 29,271,755 | 29,272 | - | - | $ | 158,781,127 | $ | (159,315,386) | $ | (504,987) | | Net Loss for the Period | - | - | - | - | | - | | (122,315) | | (122,315) | | Balance - June 30, 2021 | 29,271,755 | 29,272 | - | - | $ | 158,781,127 | $ | (159,437,701) | $ | (627,302) |

All values are in US Dollars.

	Common Stock		Preferred Stock - A			Additional				Total

| | Shares | Amount | Shares | Amount | | Capital | | Deficit | | Equity | | Balance - January 1, 2020 | 15,270,588 | 15,271 | - | - | $ | 793,789 | $ | (761,752) | $ | 47,308 | | Common Stock Issued for Product Payment - Stock Payable | 1,167 | 1 | - | - | | 1,338 | | - | | 1,339 | | Preferred Shares Issued for Services | - | - | 2,000,000 | 2,000 | | 157,998,000 | | - | | 158,000,000 | | Net Loss for the Period | - | - | - | - | | - | | (158,168,068) | | (158,168,068) | | Balance - June 30, 2020 | 15,271,755 | 15,272 | 2,000,000 | 2,000 | $ | 158,793,127 | $ | (158,929,820) | $ | (119,421) |

All values are in US Dollars.

	Common Stock		Preferred Stock - A			Additional				Total

| | Shares | Amount | Shares | Amount | | Capital | | Deficit | | Equity | | Balance - January 1, 2021 | 29,271,755 | 29,272 | - | - | $ | 158,781,127 | $ | (159,170,307) | $ | (359,908) | | Net Loss for the Period | - | - | - | - | | - | | (267,394) | | (267,394) | | Balance - June 30, 2021 | 29,271,755 | 29,272 | - | - | $ | 158,781,127 | $ | (159,437,701) | $ | (627,302) |

All values are in US Dollars.

-7-

BIOFORCE NANOSCIENCES HOLDINGS, INC., AND SUBSIDIARY

NOTES TO THE CONDENSED CONSOLIDATED UNAUDITED FINANCIAL STATEMENTS

NOTE 1 – Organization & Description of Business

The Company was incorporated in the State of Nevada on December 10, 1999 as Silver River Ventures, Inc. On February 24, 2006, the Company completed the acquisition of BioForce Nanosciences Holdings Inc. (“BioForce”), a Delaware corporation, and changed the corporate name at that time. On May 6, 2020, the Company purchased 100,000 shares of Element Acquisition Corporation for $1,000 which then became a wholly owned subsidiary. The Company on October 15, 2020 changed the name of its wholly-owned subsidiary Element Acquisition Corporation, a Wyoming corporation, to BioForce Nanosciences Holdings, Inc, a Wyoming corporation. The Company’s mission is to become a leading provider of vitamin, mineral and other nutritional supplements, powders and beverages, formulated to promote a healthier lifestyle for active individuals in all age ranges.

NOTE 2 – Summary of Significant Accounting Policies

Basis of Presentation

The accompanying condensed consolidated balance sheet has been derived from the December 31, 2020 audited financial statements and the unaudited condensed consolidated financial statements as of June 30, 2021 and 2020, have been prepared in accordance with generally accepted accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements, and should be read in conjunction with the audited financial statements and related footnotes included in our Annual report on Form 10-K for the year ended December 31, 2020 (the “2020 Annual Report”), filed with the Securities and Exchange Commission (the “SEC”). It is management’s opinion, however, that all material adjustments (consisting of normal recurring adjustments), have been made which are necessary for fair condensed consolidated financial statements presentation. Operating results for the three and six months ended June 30, 2021, are not necessarily indicative of the results of operations expected for the year ending December 31, 2021.

Principles of Consolidation

The consolidated financial statements include the accounts of Bioforce Nanosciences Holdings, Inc., and its wholly owned subsidiary, Bioforce Nanosciences Holdings, Inc., a Wyoming corporation, (the “Company”). All significant inter-company balances have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Earnings (Loss) per Share

Earnings (loss) per share of common stock are computed in accordance with FASB ASC 260 “Earnings per Share”. Basic earnings (loss) per share are computed by dividing income or loss available to common shareholders by the weighted-average number of common shares outstanding for each period. Diluted earnings per share are calculated by adjusting the weighted average number of shares outstanding assuming conversion of all potentially dilutive stock options, warrants and convertible securities, if dilutive. Common stock equivalents that are anti-dilutive are excluded from both diluted weighted average number of common shares outstanding and diluted earnings (loss) per share.

-8-

BIOFORCE NANOSCIENCES HOLDINGS, INC., AND SUBSIDIARY

NOTES TO THE CONDENSED CONSOLIDATED UNAUDITED FINANCIAL STATEMENTS

NOTE 2 – Summary of Significant Accounting Policies - continued

Stock-Based Compensation

We account for employee and non-employee stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation—Stock Compensation, which requires all share-based payments, including grants of stock options, to be recognized in the financial statements based on their fair values. The fair value of the equity instrument is charged directly to compensation expense and credited to additional paid-in capital over the period during which services are rendered.

Fair Value of Financial Instruments

The estimated fair values for financial instruments are determined at discrete points in time based on relevant market information. These estimates involve uncertainties and cannot be determined with precision. The carrying amounts of accounts payable and accrued liabilities approximate fair value given their short-term nature or effective interest rates.

Revenue Recognition

The Company implemented ASC 606, Revenue from Contracts with Customers. These included the development of new policies based on the five-step model provided in the new revenue standard, ongoing contract review requirements, and gathering of information provided for disclosures.

The Company recognizes revenue and cost of goods sold from product sales or services rendered when control of the promised goods are transferred to our clients in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods and services. To achieve this core principle, we apply the following five steps: identify the contract with the client, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to performance obligations in the contract and recognize revenues when or as the Company satisfies a performance obligation.

NOTE 3 – Recently Issued Accounting Standards

The Company has implemented all new accounting pronouncements that are in effect and is evaluating any that may impact its financial statements, including the new lease standard. The Company does not have any leases and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

NOTE 4 – Going Concern

The Company’s consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has reported recurring losses from operations and has net current liabilities and an accumulated deficit. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern.

While the Company is attempting to continue operations and generate revenues, the Company’s cash position may not be significant enough to support the Company’s daily operations. Management believes that the actions presently being taken to further implement the Company’s business plan; to expand sales with a dynamic marketing campaign and generate revenues provide the opportunity for the Company to continue as a going concern. While the Company believes in the viability of its strategy to generate revenues and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate revenues. During the three and six months ended June 30, 2021 due to lack of revenues the officers of the Company paid for all expenses through loans to the Company. This allowed the Company to continue as a going concern.

-9-

BIOFORCE NANOSCIENCES HOLDINGS, INC., AND SUBSIDIARY

NOTES TO THE CONDENSED CONSOLIDATED UNAUDITED FINANCIAL STATEMENTS

NOTE 5 – Related Party Transactions

The Company’s Director, Secretary and Acting CFO, Richard Kaiser, is the operator of Yes International, a full-service investor relations firm. He handles duties of the Company regarding his officer capacities as the Secretary and Acting CFO, but also provides investor relations services through Yes International for the Company at no charge.

During the six months ended June 30, 2021 and 2020, two board of directors paid expenses of the Company in the amount of $47,492 and $13,772, respectively. Due to related parties was $114,658 and $67,166 at June 30, 2021 and December 31, 2020, respectively.

NOTE 6 – Stock

Preferred Stock

Preferred stock consists of 100,000,000 shares authorized at $0.001 par value. 10,000,000 of these preferred shares have been separately allocated to Series A Preferred. Preferred stock can be converted into 100 shares of common stock, have dividend rights at 100 times common and have voting rights equal to 100 shares of common stock. At December 31, 2020 and 2019 there were -0- Series A Preferred shares issued and outstanding. On June 30, 2020, the Company issued two million shares of Series A preferred stock as compensation for their two board members. The preferred shares were valued at $158 million based on the market price of the Company’s common stock of $0.79 on the measurement date, given such preferred stock can be converted into 100 shares of common stock and has dividend and voting rights as though converted into common stock. On December 4, 2020, the two board of directors returned these 2,000,000 shares to be retired. In exchange the Company issued 14,000,000 common shares.

Common Stock

Common stock consists of 900,000,000 shares authorized at $0.001 par value. On November 25, 2019, the board of directors approved a 5 to 1 reverse split. At June 30, 2021 and December 31, 2020 there were 29,271,755 shares issued and outstanding, respectively.

During the year ended December 31, 2020, the Company issued 1,167 shares of common stock in exchange for product payment that was recorded in stock payable in the amount of $1,339 at December 31, 2019. The fair value of the shares issued was based on the market price of the Company’s common stock on the measurement date.

NOTE 7 – Risks and Uncertainties

Coronavirus Impact (COVID-19)

Due to the recent outbreak of the coronavirus reported in many countries worldwide, local and federal governments have issued travel advisories, canceled large scale public events and closed schools. In addition, companies have begun to cancel conferences and travel plans and require employees to work from home. Global financial markets have also experienced extreme volatility and disruptions to capital and credit markets.

-10-

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following information should be read in conjunction with our financial statements and related notes thereto included in Part I, Item 1, above.

Forward Looking Statements

Certain matters discussed herein are forward-looking statements. Such forward-looking statements contained in this Form 10-Q involve risks and uncertainties, including statements as to:

·our future strategic plans

·our future operating results;

·our business prospects;

·our contractual arrangements and relationships with third parties;

·the dependence of our future success on the general economy;

·our possible future financing; and

·the adequacy of our cash resources and working capital.

·the Covid-19 Pandemic.

From time to time, we or our representatives have made or may make forward-looking statements, orally or in writing. Such forward-looking statements may be included in, but not limited to, press releases, oral statements made with the approval of an authorized executive officer or in various filings made by us with the Securities and Exchange Commission. Words or phrases "will likely result", "are expected to", "will continue", "is anticipated", "estimate", "project or projected", or similar expressions are intended to identify "forward-looking statements". Such statements are qualified in their entirety by reference to and are accompanied by the above discussion of certain important factors that could cause actual results to differ materially from such forward-looking statements.

Covid-19 Pandemic

Management is currently aware of the global and domestic issues arising from the Covid-19 pandemic and the possible direct and indirect effects on the company's operations which could have a material adverse effect on the company's current financial position, future results of operations, or liquidity, because its current operations are limited. However, investors should also be aware of factors, which includes the possibility of Covid-19 effects on operational status, could have a negative impact on the company's prospects and the consistency of progress in the areas of revenue generation, liquidity, and generation of capital resources, once it begins to implement its business plan. These may include: (i) variations in revenue, (ii) possible inability to attract investors for its equity securities or otherwise raise adequate funds from any source should the company seek to do so, (iii) increased governmental regulation or significant changes in that regulation, (iv) increased competition, (v) unfavorable outcomes to litigation involving the company or to which the company may become a party in the future, and (vi) a very competitive and rapidly changing operating environment.

The risks identified here are not all inclusive. New risk factors emerge from time to time and it is not possible for management to predict all of such risk factors, nor can it assess the impact of all such risk factors on the company's business or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Accordingly, forward-looking statements should not be relied upon as a prediction of actual results.

The financial information set forth in the following discussion should be read with the financial statements of BioForce NanoSciences Holdings, Inc. included elsewhere herein.

-11-

Business

BioForce Nanosciences Holdings, Inc. (“BioForce or the “Company”) was previously in the business of manufacturing nano-particular measurement devices and molecular printers, but due to a lack of profitability, the subsidiary of the company that owned that technology filed for bankruptcy. That subsidiary and related technology was later bought out of bankruptcy by an unrelated third party. Subsequently, new management came into the Company to pursue a better business model and now the Company’s mission is to become a leading provider of natural vitamins, minerals and other nutritional supplements, powders and beverages, formulated to promote a healthier lifestyle for active individuals in all age ranges. The Company private labels products with key distributors and manufacturing providers.

BioForce entered into the supplement business in or about 2015. These supplements, powders and beverages offer vitamins and minerals to complement a healthy intake of protein and carbohydrates for active individuals and participants in sports.

BioForce recently changed its business plan and it is in the process of establishing a dynamic marketing campaign to achieve brand awareness of its product offerings to drive business growth through sales of nutrition supplements to retailers, sporting goods retailers, supermarkets, mass merchandisers, and online. BioForce currently markets its products through social media and telemarketing. The Company plans to expand marketing efforts with a direct marketing and B2B (Business to Business) sales campaign, with the eventual expectation to expand throughout the entire United States.

The Company proactively seeks to expand its “BioForce Eclipse” nutritional powder for use into households throughout the U.S., and the Company will approach retail stores, including health food and sporting goods stores to create a vendor relationship. During this phase, the Company will continue to try to advance its social media platform with direct online and targeted advertisements to health conscience individuals.

Nutrition retailers, grocery stores, retail pharmacies, and online stores, like Amazon, will be important channels for the Company’s Eclipse product-lines. In The USA, there are thousands of direct outlets like grocery stores, pharmacies, hospitals, department stores, medical clinics, surgery clinics, universities, nursing homes, prisons, and other facilities which are all targets of potential sales of the vitamin and mineral supplemental products.

BioForce Nanosciences Holdings, Inc. sells the BioForce Eclipse powder multivitamin and mineral supplement without non-compete and non-disclosure agreements. The Company currently private labels the powder through a manufacturer located in Virginia. The Company has a Supplier Agreement with this manufacturer that gives the Company non-exclusion rights to market the product. The distributor owns the rights to the formula for this product. If the Company can source product in a more cost-effective way without diminished quality, the Company would evaluate such opportunities when presented. Currently, the distributor who provides the private label powder provides “Consignment Terms,” which allows us to only pay for the product when it is sold.

The FDA has rules regarding the fitness for consumption of foods as well as vitamins and supplements sold to the public, and those laws apply to our product. However, our product does not require pre-clearance like a drug in order to be sold into the marketplace.

The Company in May 2020, formed a wholly-owned subsidiary, Element Acquisition Corporation, a Wyoming corporation,with unlimited common shares authorized, par value $0.001. Element Acquisition Corporation was formed to pursue potential acquisitions in the media, entertainment, media technology and sports sectors.

The Company on October 15, 2020 changed the name of its wholly-owned subsidiary Element Acquisition Corporation, a Wyoming corporation, to BioForce Nanosciences Holdings, Inc, a Wyoming corporation. Management intends to redomicile BioForce Nanosciences Holdings, Inc., a Nevada corporation, into a Wyoming corporation using its wholly-owned BioForce Nanosciences Holdings, Inc., a Wyoming corporation as the entity for the redomicile corporate action.

-12-

Transfer Agent

Our transfer agent is Transfer Online, Inc. whose address is 512 SE Salmon Street, Portland, Oregon 97214, and telephone number (503) 227-2950.

Company Contact Information

Our principal executive and subsidiary offices are located at 2020 General Booth Blvd., Unit 230, Virginia Beach, VA 23454, telephone (757) 306-6090. The information to be contained in our Internet website, www.bravomultinational.com, shall not constitute part of this report.

Current Directors

The following persons were elected to the board of directors to serve until the next annual meeting or until their replacement is elected:

Merle Ferguson	Director
Richard Kaiser	Director

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overall Operating Results:

Three Months – June 30, 2020 and 2019 Statements

The Sales Revenue from the Company’s BioForce Eclipse vitamin supplements for the three months ended June 30, 2021and for the three months ended June 30, 2020 were $-0- and $-0-, respectively. During the three months ended June 30, 2021 and 2020 the Company received no orders, -0- units of its Bioforce Eclipse supplement product.

The Cost of Goods Sold for the three months ended June 30, 2020 and 2021 was $-0- .

Gross Margins for the three months ended June 30, 2020 and 2021 was 0% from the sale of -0- units of the BioForce Eclipse supplement product.

Gross Profit for the three months ended June 30, 2020 and 2021 was $-0- .

Operating expenses for three months ended June 30, 2021, totaled $122,315 from Board of Director compensation and General and Administrative Expenses, compared to $126.710 for the three months ended June 30, 2021. This decrease in June 30, 2021 compared to the same period ended June 30, 2020 was attributed to lower expenses from professional services rendered.

-13-

Six Months – June 30, 2021 and 2020 Statements

The Sales Revenue from the Company’s "BioForce Eclipse" vitamin supplement for the six months ended June 30, 2021 and 2020 were $-0-, Company sold no units of its Bioforce Eclipse" vitamin supplement.

The Cost of Sales for the six months ended June 30, 2021 and 2020 were $-0-.

Gross Margins for the six months ended June 30, 2021 and 2020 were 0% from the sale of -0- units of the “BioForce Eclipse” supplement product.

Gross Profit for the six months ended June 30, 2021and 2020 were $-0-.

Operating expenses for six months ended June 30, 2021, totaled $267,395 for Board of Director Compensation and General and Administrative Expenses, compared to $158,168,068 for the six months ended June 30, 2020. This decrease during the same six month period ended June 30, 2021 was attributed to a decrease in Board of Director fees compared to the six months ended June 30, 2020 when preferred shares were issued and recognized for the implementation of the accounting rules for the handling of equity based compensation.

Net Loss:

Net loss for the three month ended June 30, 2021 and 2020 were $122,315 and $126,710 , respectively. Net loss for the six month ended June 30, 2021 and 2020 were $267,394 and $158,168,068, respectively.

Liquidity and Capital Resources:

As of June 30, 2021, the Company’s assets totaled $27,405, which consisted of cash and prepaid expenses. Our total liabilities were $654,707 from accounts payable and accrued expenses, accrued director compensation expenses and amounts due to related parties. As of June 30, 2021, the Company had an accumulated deficit of $159,437,701 and working capital deficit $627,302.

As indicated herein, we need capital for the implementation of our business plan, and we will need additional capital for continuing our operations. We do not have sufficient revenues to pay our operating expenses at this time. Unless the company is able to raise working capital, it is likely that the Company will either have to cease operations or substantially change its methods of operations or change its business plan (See Note 4 in Financial Statements). For the next 12 months the Company has a written commitment from its CEO in Mr. Merle Ferguson's employment contract ( See Exhibit 10.01) to advance funds as necessary in meeting the Company's operating requirements.

BioForce NanoSciences Holdings, Inc. does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company, or any of its subsidiaries’ operating results, financial position, or cash flow.

Cash Provided by (Used in) Operating Activities

Net cash used in operating activities for the six months ended June 30, 2021 and 2020 were $60,052 and $60,406, respectively. The decrease amount was attributed to General and Administrative cost that were used in operational and professional fee expenses.

Cash Flows from Investing Activities

Net cash used in investing activities was $-0- for both the six month periods ended June 30, 2021 and 2020.

-14-

Cash Provided by Financing Activities

Net cash provided by financing activities was $47,492 for six month ended June 30, 2021 from proceeds from Related Parties, and was $47,376 for six month ended June 30, 2020 from proceeds from Related Parties .

Critical Accounting Policies

Our financial statements and accompanying notes are prepared in accordance with generally accepted accounting principles in the United States. Preparing financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenue, and expenses. These estimates and assumptions are affected by management’s application of accounting policies. Critical accounting policies include revenue recognition and stock-based compensation. The Company has implemented all new accounting pronouncements that are in effect and is evaluating any that may impact its financial statements, including revenue recognition. The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Revenue Recognition

In accordance with ASC Topic 606, Revenue from Contracts with Customers ("ASC 606"), revenues are recognized when control of the promised goods or services is transferred to our clients, in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods and services. To achieve this core principle, we apply the following five steps: (1) Identify the contract with a client; (2) Identify the performance obligations in the contract; (3) Determine the transaction price; (4) Allocate the transaction price to performance obligations in the contract; and (5) Recognize revenues when or as the company satisfies a performance obligation.

We adopted this ASC on January 1, 2018. Although the new revenue standard is expected to have an immaterial impact, if any, on our ongoing net income, we did implement changes to our processes related to revenue recognition and the control activities within them.

Stock-Based Compensation

We account for employee and non-employee stock-based compensation in accordance with the guidance of FASB ASC Topic 718,Compensation—Stock Compensation, which requires all share-based payments, including grants of stock options, to be recognized in the financial statements based on their fair values. The fair value of the equity instrument is charged directly to compensation expense and credited to additional paid-in capital over the period during which services are rendered.

Recent Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect and is evaluating any that may impact its financial statements, including revenue recognition. The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

-15-

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Reverse Stock Split

We were authorized to issue 900,000,000 shares of our common stock, of which 15,270,588 shares were outstanding taking into account the one-for-five (1-for-5) reverse stock split effective February 28, 2020. Our shares of common stock are held by approximately 231 stockholders of record. The number of record holders was determined from the records of our transfer agent and does not include beneficial owners of our common stock whose shares are held in the names of various securities brokers, dealers, and registered clearing agencies. In addition to our authorized common stock, BioForce Nanosciences Holdings, Inc. is authorized to issue 100,000,000 shares of preferred stock, par value at $0.001 per share. Based on the amended Articles of Incorporation the Company has 10,000,000 Series 'A' Preferred which have voting and conversion rights of 100 common shares, par value $0.001(see Exhibit 3.2); leaving a balance of 90,000,000 "Blank Check" Preferred. There are no Series 'A' Preferred shares issued or outstanding.

Going Concern

We have incurred net losses since our inception. We anticipate incurring additional losses before realizing growth in revenue and we will depend on additional financing in order to meet our continuing obligations and ultimately to attain profitability. Our ability to obtain additional financing, whether through the issuance of additional equity or through the assumption of debt, is uncertain. These conditions raise substantial doubt as to the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the uncertainty about our ability to continue our business.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Principal Executive Officer and Principal Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in the Securities Exchange Act of 1934 Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Quarterly Report on Form 10-Q. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

-16-

Based on our evaluation, our Principal Executive Officer and Principal Financial Officer, after considering the existence of material weaknesses identified, determined that our internal control over financial reporting disclosure controls and procedures were not effective as of June 30, 2021.

We identified the following deficiencies which together constitute a material weakness in our assessment of the effectiveness of internal control over financial reporting as of March 31, 2021:

The Company has inadequate segregation of duties within its cash disbursement control design.

Changes in Internal Control Over Financial Reporting

There have been no changes in the Company’s internal control over financial reporting that occurred during the Quarter ended June 30, 2021 to have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Coronavirus Impact (COVID-19)

We are unable to predict the impact of the coronavirus on our operations at this time. Adverse events such as health-related concerns about working in our offices, the inability to travel, potential impact on our business partners and customers, and other matters affecting the general work and business environment could harm our business and delay the implementation of our business strategy. The adverse events may also adversely impact our ability to raise capital or to continue as a going concern. We continue to monitor the recent outbreak of the coronavirus on our operations. The global economic slowdown and the other risks and uncertainties associated with the pandemic could have a material adverse effect on our business, financial condition, results of operations and growth prospects. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company's business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties which the Company faces.

-17-

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

At this time, there are no materials pending legal proceedings to which the Company is a party or as to which any of its property is subject, and no such proceedings are known to the Company to be threatened or contemplated against it.

ITEM 1A. RISK FACTORS

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and, as such, are not required to provide the information under this Item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINING SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION.

On April 16, 2021, the Company entered into a consulting agreement with Mr. Aldo Dalla-Vecchia of RSDL Enterprises to provide general consulting services to BFNH's management team. The agreement was for two months, ending June 16, 2021, for a total cash consideration of $4,500, $2,250 per month (See Exhibit 10.1)

-18-

ITEM 6. EXHIBITS

Index to Exhibits.

Exhibit No. Description of Exhibit

3.1

Certificate of Incorporation*

3.2

Amended Articles of Certificate of Incorporation (previously filed at Exhibit 3.1 on DEF 14C-Definative Information Statement )*

3.3

Bylaws (previously filed as Exhibit 3.2 on FORM 10)*

10.1

Consulting Contract RSDL Enterprises-April 16, 2021+

31.1

Amended Certification Chief Executive Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to §302 of the Sarbanes-Oxley Act of 2002.+

31.2

Amended Certification Chief Executive Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to §302 of the Sarbanes-Oxley Act of 2002.+

32.1

Amended Certification Chief Executive Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002.+

32.2

Amended Certification Chief Executive Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002.+

101 Interactive Financial Data XBRL Extensions.+

* Previously filed

filed herewith

SIGNATURES

In accordance with the requirements of the Exchange Act, the Registrant caused this Amended report to be signed on its behalf by the undersigned, thereunto duly authorized.

BIOFORCE NANOSCIENCES HOLDINGS, INC.

Dated: July 30, 2021	By: /s/ Merle Ferguson<br><br> <br>Merle Ferguson<br><br> <br>Chief Executive Officer
	By: /s/Richard Kaiser<br><br> <br>Richard Kaiser<br><br> <br>Acting Chief Financial Officer

-19-

Exhibit 10.1

CONSULTINGAGREEMENT

BioForce NanoSciences Holdings, Inc. desires to have services provided by Aldo Dalla-Vecchia.

Therefore, the parties agree as follows:

1.DESCRIPTION OF SERVICES.

Beginning on April 16, 2021, Aldo Dalla-Vecchia will provide the following services (collectively, the "Services"): General Consulting for Management

2.PERFORMANCE OF SERVICES.

The manner in which the Services are to be performed and the specific hours to be worked by Aldo Dalla-Vecchia shall be determined by Aldo Dalla-Vecchia. BioForce NanoSciences Holdings, Inc. will rely on Aldo

Dalla-Vecchia to work as many hours as may be reasonably necessary to fulfill Aldo Dalla-Vecchia's obligations under

this Agreement.

3.PAYMENT.

BioForce NanoSciences Holdings, Inc. will pay a fee to Aldo Dalla-Vecchia for the Services in the amount of $2,250 per month for a total of $4,500.00. This fee shall be payable in a lump-sum upon within 48 hours upon signing agreement.

4.NEW PROJECT APPROVAL.

Aldo Dalla-Vecchia and BioForce NanoSciences Holdings, Inc. recognize that Aldo Dalla-Vecchia's Services will include working on various projects for Bravo Multinational Inc. Aldo Dalla-Vecchia shall obtain the approval of BioForce NanoSciences Holdings, Inc. prior to the commencement of a new project.

5.TERM/TERMINATION.

This Agreement shall terminate automatically on June 16, 2021 at 5:30PM ET.

6.RELATIONSHIP OF PARTIES.

It is understood by the parties that Aldo Dalla-Vecchia is an independent contractor with respect to Bravo Multinational Inc, and not an employee of BioForce NanoSciences Holdings, Inc. BioForce NanoSciences Holdings, Inc. will not provide fringe benefits, including health insurance benefits, paid vacation, or any other employee benefit, for the benefit of Aldo Dalla-Vecchia.

7.INDEMNIFICATION.

Aldo Dalla-Vecchia agrees to indemnify and hold harmless BioForce NanoSciences Holdings, Inc. from all claims, losses, expenses, fees including attorney fees, costs, and Judgments that may be asserted against BioForce NanoSciences Holdings, Inc. that result from the acts or omissions of Aldo Dalla-Vecchia, Aldo Dalla-Vecchia's employees, if any, and Aldo Dalla-Vecchia's agents.

-1-

8.RETURN OF RECORDS.

Upon termination of this Agreement, Aldo Dalla-Vecchia shall deliver all records, notes, data, memoranda, models, and equipment of any nature that are in Aldo Dalla-Vecchia's possession or under Aldo Dalla-Vecchia's control and that BioForce NanoSciences Holdings, Inc. 's property or relate to BioForce NanoSciences Holdings, Inc.’s business.

9.NOTICES.

All notices required or permitted under this Agreement shall be in writing and shall be deemed delivered when delivered in person or deposited in the United States mail, postage prepaid, addressed as follows:

IF for Bravo Multinational Inc:

BioForce NanoSciences Holdings, Inc.

Richard Kaiser

Secretary

2020 General Booth Blvd Suite 230 Virginia Beach, Virginia 23454

IF for Aldo Dalla-Vecchia:

RSDL Enterprises,3700 Colchester Road Lansing, Michigan 48906

Such address may be changed from time to time by either party by providing written notice to the other in the manner set forth above.

10.ENTIRE AGREEMENT.

This Agreement contains the entire agreement of the parties and there are no other promises or conditions in any other Agreement(s )whether oral or written. This Agreement supersedes any prior written or oral agreements between the

parties.

11.AMENDMENT.

This Agreement may be modified or amended if the amendment is made in writing and is signed by both parties.

12.SEVERABILITY.

If any provision of this Agreement shall be held to be invalid or unenforceable for any reason, the remaining provisions shall continue to be valid and enforceable. If a court finds that any provision of this Agreement is invalid or unenforceable, but that by limiting such provision it would become valid and enforceable, then such provision shall be deemed to be written, construed, and enforced as so limited.

-2-

13.WAIVER OF CONTRACTUAL RIGHT.

The failure of either party to enforce any provision of this Agreement shall not be construed as a waiver or limitation of that party's right to subsequently enforce and compel strict compliance with every provision of this Agreement.

14. APPLICABLELAW.

This Agreement shall be governed by the laws of the State of Virginia.

15.INTERRUPTION OF SERVICE.

Either party shall be excused from any delay or failure in performance required hereunder if caused by reason of any occurrence or contingency beyond its reasonable control, including, but not limited to, acts of God,

acts of war, fire, insurrection, laws proclamations, edits, ordinances or regulations, strikes, lock-outs or other serious labor disputes, riots, earthquakes, floods, explosions or other acts of nature. The obligations and rights of the party so excused shall be extended on a day-to-day basis for the time period equal to the period of such excusable interruption. When such events have abated, the parties' respective obligations hereunder shall resume. In the event the interruption of the excused party's obligations continues for a period in excess of thirty (30) days, either party shall have the right to terminate this Agreement upon ten (10) days' prior written notice to the other party.

16.ASSIGNMENT.

Aldo Dalla-Vecchia agrees that it will not assign, sell, transfer, delegate or otherwise dispose of any rights or obligations under this Agreement without the prior written consent of Bravo Multinational Inc. Any purported assignment,

transfer, or delegation shall be null and void. Nothing in this Agreement shall prevent the consolidation of BioForce NanoSciences Holdings, Inc. with, or its merger into, any other corporation, or the sale by BioForce NanoSciences Holdings, Inc. of all or substantially all of its properties or assets, or the assignment by BioForce NanoSciences Holdings, Inc. of this Ageement and the performance of its obligations hereunder to any successor in interest or any Affiliated Company. Subject to the foregoing, this Agreement shall be binding upon and shall inure to the benefit of the parties and their respective heirs, legal representatives,successors, and permitted assigns, and shall not benefit any person or

entity other than those enumerated above.

This Agreement shall be signed on behalf of BioForce NanoSciences Holdings, Inc.by Richard Kasier, Secretary and on behalf of Aldo Dalla-Vecchia by Aldo Dalla-Vecchia, Principal , RSDL RSDI Enterprises and effective as of

the date first above written.

This Consulting Agreement is executed and agreed to by:

/s/ Richard Kaiser

____________________________

Richard Kaiser

BioForce NanoSciences Holdings, Inc.

Date: April 16, 2021

/s/ Aldo Dalla-Vecchia

________________________

Aldo Dalla-Vecchia

RSDL Enterprises

Date: April 16, 2021

-3-

Exhibit 31.1

AMENDED CERTIFICATION CHIEF EXECUTIVEOFFICER

I, Merle Ferguson, hereby certify that:

(1) I have reviewed this quarterly report on Amended Form 10-Q/A of Bioforce Nanosciences Holdings, Inc..;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5) The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. >

Dated: July 30,<br> 2021	/s/Merle Ferguson<br><br> <br>Merle Ferguson<br><br> <br>Chief Executive Officer

Exhibit 31.2

AMENDED CERTIFICATION CHIEF FINANCIALOFFICER

I, Richard Kaiser, hereby certify that:

(1) I have reviewed this quarterly Amended report on Form 10-Q/A of BioForce Nanosciences Holdings, Inc..;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: July 31,<br> 2021	/s/Richard Kaiser<br><br> <br>Richard Kaiser<br><br> <br>Acting Chief Financial<br> Officer

Exhibit 32.1

AMENDED CERTIFICATION PURSUANT TO SECTION 906 OF THESARBANES-OXLEY ACT OF 2002

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), the undersigned officers of Bioforce Nanosciences Holdings, Inc., a Nevada corporation (the "Company"), do hereby certify, to the best of their knowledge, that:

The Amended Quarterly Report on Form 10-Q/A for the period ending June 30, 2021 (the "Report") of the Company complies in all material respects with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: July 30,<br> 2021	/s/Merle Ferguson<br><br> <br>Merle Ferguson<br><br> <br>Chief Executive<br> Officer

Exhibit 32.2

AMENDEDCERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The Amended Quarterly Report on Form 10-Q/A for the period ending June 30, 2021 (the "Report") of the Company complies in all material respects with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:July 30, 2021<br>	/s/Richard Kaiser<br><br> <br>Richard Kaiser<br><br> <br>Acting Chief Financial<br>Officer

10-Q/A

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q/A

Commission file number: 000-51074

BIOFORCE NANOSCIENCES HOLDINGS, INC.

Explanatory Note:

TABLE OF CONTENTS

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

BioForce Nanosciences Holdings, Inc., and Subsidiary

BioForce Nanosciences Holdings, Inc., and Subsidiary

BioForce Nanosciences Holdings, Inc., and Subsidiary

BioForce Nanosciences Holdings, Inc., and Subsidiary

BIOFORCE NANOSCIENCES HOLDINGS, INC., AND SUBSIDIARY

NOTES TO THE CONDENSED CONSOLIDATED UNAUDITED FINANCIAL STATEMENTS

NOTE 1 – Organization & Description of Business

NOTE 2 – Summary of Significant Accounting Policies

Basis of Presentation

Principles of Consolidation

Use of Estimates

Earnings (Loss) per Share

BIOFORCE NANOSCIENCES HOLDINGS, INC., AND SUBSIDIARY

NOTES TO THE CONDENSED CONSOLIDATED UNAUDITED FINANCIAL STATEMENTS

NOTE 2 – Summary of Significant Accounting Policies - continued

Stock-Based Compensation

Fair Value of Financial Instruments

Revenue Recognition

The Company implemented ASC 606, Revenue from Contracts with Customers. These included the development of new policies based on the five-step model provided in the new revenue standard, ongoing contract review requirements, and gathering of information provided for disclosures.

NOTE 3 – Recently Issued Accounting Standards

NOTE 4 – Going Concern

BIOFORCE NANOSCIENCES HOLDINGS, INC., AND SUBSIDIARY

NOTES TO THE CONDENSED CONSOLIDATED UNAUDITED FINANCIAL STATEMENTS

NOTE 5 – Related Party Transactions

NOTE 6 – Stock

Preferred Stock

Common Stock

NOTE 7 – Risks and Uncertainties

Coronavirus Impact (COVID-19)

3.1

3.2

3.3

10.1

31.1

31.2

32.1

32.2

101 Interactive Financial Data XBRL Extensions.+